Takeda, Astellas Report First Revenue Declines As Generics Intrude
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical and Astellas Pharma, Japan's largest drug makers, say they are suffering heavily from generic raids on their products as patent protections expire